Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and safety of Eylea in proliferative diabetic retinopathy
2013-001856-36Phase 2Active
- Sponsor
- CHU de Poitiers
- Start
- Feb 2016
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of aflibercept in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by CHU de Poitiers. Started Feb 2016; status: active.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on 2013-001856-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001856-36.